Zacks Investment Research Lowers Kura Oncology (NASDAQ:KURA) to Hold

Zacks Investment Research lowered shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Other equities research analysts have also recently issued research reports about the stock. BidaskClub cut shares of Xperi from a sell rating to a strong sell rating in a report on Wednesday, June 19th. Leerink Swann set a $27.00 target price on shares of Kura Oncology and gave the company a buy rating in a report on Saturday, June 15th. ValuEngine raised shares of United Overseas Bank from a sell rating to a hold rating in a report on Monday, June 17th. Oppenheimer set a $13.00 target price on shares of Alpine Immune Sciences and gave the company a buy rating in a report on Tuesday, March 19th. Finally, Cowen reissued a buy rating on shares of Kura Oncology in a report on Monday, June 17th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $28.00.

Shares of KURA stock opened at $20.15 on Wednesday. The firm’s fifty day simple moving average is $18.43. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.80 and a quick ratio of 13.80. Kura Oncology has a 1 year low of $10.20 and a 1 year high of $22.00. The company has a market cap of $769.53 million, a PE ratio of -11.72 and a beta of 2.51.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. As a group, analysts forecast that Kura Oncology will post -1.71 EPS for the current fiscal year.

In other news, insider Antonio Gualberto sold 18,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $21.11, for a total transaction of $379,980.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.30% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Great Point Partners LLC grew its position in shares of Kura Oncology by 30.7% during the 4th quarter. Great Point Partners LLC now owns 2,769,527 shares of the company’s stock valued at $38,884,000 after purchasing an additional 650,421 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Kura Oncology during the 4th quarter valued at $2,222,000. California Public Employees Retirement System grew its position in shares of Kura Oncology by 228.6% during the 4th quarter. California Public Employees Retirement System now owns 153,300 shares of the company’s stock valued at $2,152,000 after purchasing an additional 106,641 shares in the last quarter. Fosun International Ltd grew its position in shares of Kura Oncology by 49.8% during the 1st quarter. Fosun International Ltd now owns 305,958 shares of the company’s stock valued at $4,972,000 after purchasing an additional 101,724 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of Kura Oncology during the 1st quarter valued at $1,073,000. Hedge funds and other institutional investors own 83.93% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Article: Depreciation

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.